Related Experiment Video
Updated: Apr 29, 2026
07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
10.7K
Apolipoprotein E in Alzheimer's disease: an update
Jin-Tai Yu1, Lan Tan, John Hardy
1Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao 266071, China; email: yu-jintai@163.com , dr.tanlan@163.com.
Annual Review of Neuroscience
|May 14, 2014
Summary
Late-onset Alzheimer's disease (LOAD) is complex, with Apolipoprotein E (APOE) as a key genetic risk factor. APOE influences disease through multiple pathways, informing new therapeutic strategies and diagnostic approaches.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Late-onset Alzheimer's disease (LOAD) accounts for the majority of AD cases and is highly heritable.
- Apolipoprotein E (APOE) is the primary genetic risk factor for LOAD, exhibiting semidominant inheritance.
Purpose of the Study:
- To explore the multifaceted role of APOE in Alzheimer's disease pathogenesis.
- To review emerging therapeutic strategies targeting APOE.
- To highlight the diagnostic and prognostic utility of APOE genotyping.
Main Methods:
- Review of existing literature on APOE's role in AD.
- Analysis of various therapeutic interventions targeting APOE.
- Evaluation of APOE genotyping in clinical applications.
Main Results:
- APOE influences AD through both amyloid-β-dependent and independent mechanisms.
- Multiple therapeutic strategies targeting APOE are under development.
- APOE genotyping shows promise for AD diagnosis, risk assessment, and treatment.
Conclusions:
- APOE is a critical determinant of LOAD risk and progression.
- Targeting APOE offers a promising avenue for AD therapy.
- APOE genotyping is valuable for personalized AD management.
More Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
34
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
34
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:22Dementia l: Introduction
33
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
33
03:03Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K